Evoke Pharma (EVOK) said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.
The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.
It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.
Shares of the drug developer more than doubled in premarket activity.
Price: 11.50, Change: +6.37, Percent Change: +124.17
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。